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1. SUMMARY 
 
Purpose We aimed to study drug interactions and dose adjustments for renal impairment in 
the discharge medication of surgical inpatients, and to evaluate strengths and limitations of 
Clinical Decision Support software (CDSS) for this task. 
Methods Cross-sectional study in 509 surgical patients of a primary care hospital. We 
developed a customized interface for the CDSS MediQ, which we used for automated 
retrospective identification of drug interactions in the patients’ discharge medication. Clinical 
relevance of interactions was evaluated based on the Zurich Interaction System (ZHIAS) that 
incorporates the Operational Classification of Drug Interactions (ORCA). Prescriptions were 
further analyzed for recommended dose adjustments in patients with a GFR <60 ml/min. 
Results In 509 patients with 2,729 prescriptions MediQ generated 2,558 interaction alerts 
and 1,849 comments. Among those there were 10 “high danger” and 551 “average danger” 
alerts that we reclassified according to ORCA criteria. This resulted in 10 contraindicated 
combinations, 77 provisionally contraindicated combinations, 310 with a conditional and 164 
with a minimal risk of adverse outcomes. The ZHIAS classification also provides categorical 
information on expected adverse outcomes and management recommendations, which are 
presented in detail. We identified 56 prescriptions without recommended dose adjustment for 
impaired renal function. 
Conclusions CDSS identified a large number of drug interactions in surgical discharge 
medication, but according to ZHIAS criteria only a minor fraction appears to involve a 
substantial risk. CDSS should aim at reducing over-alerting and improve usability in order to 
become more efficacious regarding the prevention of adverse drug events in clinical practice.
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2. INTRODUCTION 
Drug interactions and resulting adverse drug events (ADE) are important challenges for 
pharmacotherapy. They cause considerable morbidity, mortality and costs, and have been 
estimated to be responsible for 1% of all hospital admissions [1-5]. Computerized physician 
order entry (CPOE) combined with clinical decision support software (CDSS) has been 
proposed as a valuable tool to prevent critical interactions and also to guide dose adjustment 
in patients with impaired renal function. On the one hand, several studies presented 
encouraging results [6, 7]. For example, one study was able to demonstrate a significant 
81% reduction in medication errors after the introduction of CPOE with CDSS [8]. But on the 
other hand, several more recent studies concluded that commonly used CDSS suffer from 
“over-alerting”, and that the resulting “alert-fatigue” among physicians is an important reason 
why they often fail to effectively improve medication safety in clinical practice [9-12]. 
Furthermore, the frequency of specific critical medication problems varies between different 
specialties and settings. New approaches may therefore first aim to analyze local safety 
issues with high efficiency, as this may subsequently support the development of targeted 
local measures in order to improve pharmacotherapy. In particular, we found that more data 
is needed for surgical inpatients in order to evaluate medication safety for this population. 
The current study therefore had two major aims. First, to describe and quantify medication 
safety with regard to drug interactions and renal dose adjustments in patients discharged 
from surgical care in a regional Swiss hospital using a new highly efficient CDSS interface for 
retrospective interaction analysis. Second, to improve the specificity of CDSS in identifying 
clinically relevant drug interactions and providing related practical prescribing information. 
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3. MATERIAL AND METHODS 
 
Study design 
We conducted a cross-sectional study in all surgical patients discharged between 1 January 
and 31 October 2009 from a primary care regional hospital, including patients from general 
surgery, orthopedics, urology, otorhinolaryngology and reconstructive surgery. There were 
no exclusion criteria except admissions for less than four nights; patients with a shorter stay 
were excluded in order to assure that pharmacotherapy was actively managed and well 
documented by the treating surgeons. The regional ethics committee had approved the study 
protocol including access to the hospital’s clinical information system for study purposes. 
Pharmacotherapy at discharge, demographics, medical diagnoses and laboratory test results 
were retrospectively retrieved for each patient from their original medical records and the 
hospital’s clinical information system, and data of all patients was stored in an anonymized 
master file. The latest available value for serum creatinine before discharge was used to 
estimate renal function according to the MDRD-GFR formula [13]. All drugs were then 
matched to their corresponding ATC codes, and single drugs that contained several active 
ingredients were split into their component substances and treated as separate prescriptions 
for all further analyses. 
Subsequently we analyzed the data for the following outcomes of interest: 1. frequency and 
severity grading of drug interactions according to the commercially available CDSS MediQ; 
2. extended classification and evaluation of the clinical relevance of interactions identified by 
MediQ according to the Zurich Interaction System (ZHIAS); 3. compliance with 
recommended dose adjustments in patients with an estimated GFR <60 ml/min based on 
MediQ alerts, Aronoff’s Drug Prescribing in Renal Failure [14], and the manufacturers’ 
national prescribing information (Arzneimittel-Kompendium der Schweiz). Figure 1 shows an 
overview of the study procedures and global results. 
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MediQ and development of a customized interface for mass analysis 
MediQ is a commercial CDSS for use as an Internet application (www.mediq.ch). The user 
manually enters concomitantly prescribed drugs for individual patients, and MediQ then 
identifies interactions and provides the following output. First, a four-level categorical severity 
grading that MediQ describes as: 3 = ”high” or “strong interaction”; 2 = ”average” or “clinically 
relevant interaction”; 1 = “low” or an interaction that is “relevant in exceptional cases”; 0 = “no 
interaction” or additional comments. This information is also presented in a matrix overview. 
Second, detailed free text information for each interaction. Third, additional tables that 
present pharmacokinetic effects on metabolizing enzymes and drug transporters as well as 
pharmacodynamic effects on the central nervous system for individual substances. 
Because the manual entry of prescriptions for each patient would not be efficient for our 
purposes we developed, in collaboration with MediQ, a customized data interface for mass 
analysis. This allowed us to upload one structured text file over the Internet that contained an 
anonymous study number and the corresponding ATC codes of concomitantly prescribed 
drugs for each patient. Exactly the same analyses as for the usual Internet application were 
then executed on the MediQ server. The results could subsequently be downloaded over the 
Internet and imported into statistical software for further analyses. Because MediQ’s 
knowledge database is continuously updated it is of note that the interaction analyses 
presented in this study were all executed in July 2010. 
 
ZHIAS classification 
ZHIAS is an extended drug interaction classification system that was developed at our 
department during the conduct of this and other related studies. It features four major 
dimensions plus free text fields. The first dimension uses the well established and 
documented five-level grading according to the Operational Classification of Drug 
Interactions (ORCA) criteria [15]. Briefly, ORCA’s five operational levels are defined as 
follows: Grade 1 = “contraindicated combination”. The risk of such a combination always 
outweighs the benefit. Grade 2 = “provisionally contraindicated”. The combination should be 
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avoided unless interaction is desired or no alternative is available, monitoring may be 
necessary. Grade 3 = “conditional risk”. Monitoring or alternatives should be considered. 
Grade 4 = “minimal risk”. No special action is needed. Grade 5 = “no interaction”. ZHIAS’s 
other 3 major dimensions use dichotomous variables that relate to patient management, 
interaction mechanisms and adverse effects with an increased risk resulting from an 
interaction (see Table 4). For the current study an expert panel consisting of a surgeon (TF), 
two pharmacists (OZ and AF), and a clinical pharmacologist (SR) discussed the ZHIAS 
classifications of identified interactions until common agreement was achieved. For our 
assessments we referred to original and secondary literature, including but not limited to 
Hansten and Horn’s Drug Interactions: analysis and management [16], and Stockley’s Drug 
Interactions [17]. 
 
Data analysis 
Data analysis was descriptive with presentation of results in text, tables and figures, and 
calculation of medians, means and proportions as appropriate. Data management and 
analyses were performed with STATA 11.1 for MacOS X (STATA corporation, College 
Station, TX, USA) and SPSS 19 for Windows (SPSS, Inc., Chicago, IL, USA). 
 
 
4. RESULTS 
 
Selection and characteristics of the study population 
Demographic data of 552 consecutive surgical patients hospitalized for at least four nights at 
the Department of Surgery was retrieved from the hospital’s electronic information system. 
Thereafter the patients’ discharge medication was abstracted from their original medical 
records including discharge letters. Consequently, 43 patients were excluded because they 
had only one or no prescription. Characteristics of all remaining 509 included patients are 
presented in Table 1. Mean age was 60.4 years with a median and range of 70.5 (8 - 99) 
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years. The median number of concomitantly prescribed substances per patient was 5 (range 
2 - 17), and Table 1 also presents polypharmacy distribution over three broad categories. 
Frequency of prescriptions over drug classes is shown in Table 2. NSAIDs with paracetamol 
(acetaminophen) and metamizol (dipyrone) were the most commonly prescribed drug class, 
followed by antithrombotics and cardiovascular agents. 
 
Identification and evaluation of drug interactions 
Automated analysis using MediQ generated 2,558 interaction alerts and 1,849 additional 
comments (Fig. 1). As expected, the number of interaction alerts per patient markedly 
increased with a higher number of concomitantly prescribed substances (Fig. 2). 
Table 3 presents results of the automated drug interaction analysis using MediQ along with 
our subsequent reclassification of MediQ “high” and “average” danger alerts according to 
ORCA criteria. Out of 10 combinations considered by MediQ as involving a “high danger” 
interaction none was classified as contraindicated and only one as provisionally 
contraindicated according to ORCA criteria; out of 551 prescriptions considered by MediQ as 
involving an “average danger” 10 were classified as contraindicated and 76 as provisionally 
contraindicated. The full evaluation of all MediQ high danger and average danger interaction 
alerts showing all ZHIAS dimensions is presented in Table 4. Evaluation regarding 
management of interactions according to ZHIAS concluded that 28.6% of provisionally 
contraindicated combinations and 21.9% of combinations with a conditional risk were most 
likely actually desired combinations with an acceptable risk-benefit ratio under the condition 
that patients are appropriately monitored. Nevertheless, at the same time in more than 70% 
there may exist alternative treatments with a possibly more favorable risk-benefit ratio. 
Regarding mechanisms, pharmacodynamic interactions were most frequent over all ORCA 
classes, and increased drug effects, particularly increased risk of bleeding, were the most 
frequently encountered potential adverse consequences resulting from interactions. 
Specific interacting combinations with the highest danger rating according to MediQ or 
ORCA are presented in Table 5. MediQ classified 6 specific combinations as “high danger”. 
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In these cases ORCA criteria emphasize that even if the potential adverse effect may be 
severe, all of these interactions could be managed with appropriate monitoring such as for 
hyperkalemia or QTc prolongations, followed by dose adjustment or stop of therapy if 
necessary. In contrast, those combinations with the highest ORCA rating may not 
necessarily be driven by a very high risk or severity of an adverse event: in eight out of ten 
cases the combined drugs have the same mechanism of action, and for two the weak 
evidence supporting ginkgo’s efficacy led to our assessment of a generally unfavorable risk-
benefit ratio. In addition, Table 6 also presents all specific drug interactions classified by 
ZHIAS as ORCA 2 (“provisionally contraindicated”), and the 10 most frequent classified as 
ORCA 3 (“conditional risk”). This overview also shows that MediQ identified a large number 
of interactions that may increase the risk of bleeding in the studied surgical population and 
assigns them an “average” risk. The multidimensional ZHIAS evaluation additionally 
distinguishes a more relevant bleeding risk if NSAIDs are combined with the oral 
anticoagulant phenprocoumon from a lower risk when combined with low-dose heparins, and 
recognizes that low-dose aspirin combined with phenprocoumon may carry a substantial risk 
but that this is often a desired combination. 
 
Dose adjustment in patients with impaired renal function 
Creatinine measurements and corresponding MDRD-GFR estimations were available for 473 
(92.9%) of all 509 included patients, and 65 patients (12.8%) had renal impairment with a 
GFR below 60 ml/min. Those patients had a total of 448 prescriptions for 61 distinct 
substances, which we analyzed for compliance with recommended dose adjustments. 
According to MediQ 26 substances accounting for 247 prescriptions in 58 patients require 
dose adjustment in case of impaired renal function, and we identified a failure to comply with 
recommended dose adjustment for 56 prescriptions in 44 patients. These are presented in 
Table 7, along with our assessment of 14 prescriptions having a major and 42 a minor risk of 
resulting in a related adverse event. 
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5. DISCUSSION 
The current study used a customized interface with the CDSS MediQ for the retrospective 
identification of drug interactions and of substances that require dose adjustment for renal 
impairment in the discharge medication of surgical inpatients. MediQ was able to detect a 
very large number of (potential) drug interactions and therefore readily demonstrates the 
typical major strength as well as limitation of CDSS. Although this study was not designed to 
evaluate the sensitivity of MediQ to detect drug interactions, our results and the fact that its 
database contains about 2,000 substances and 20,000 detailed comments on related drug 
interactions suggests that MediQ is indeed a highly sensitive tool for the detection of 
interactions. On the other hand, our further evaluation based on ORCA and extended ZHIAS 
criteria concluded that only a minor fraction of alerts generated by MediQ is associated with a 
substantial risk that would require medication changes. This is of particular concern as such 
low specificity with regard to clinically relevant information is expected to compromise a 
physician’s compliance to use such a system in daily practice [9-12]. In contrast, previous 
studies have shown that focused information that has been pre-selected by clinical 
pharmacologists and pharmacists and then clearly communicated to treating physicians does 
have a long-lasting reducing effect on the prescription of interacting drug combinations [5]. 
Our own experience from daily safety ward rounds at a university hospital are also in 
agreement with this finding, but in most clinical settings such resource intensive services are 
not routinely available. Furthermore, one-dimensional three level “traffic light” grading 
systems such as one used by MediQ do not necessarily correlate with clinical relevance of 
alerts [15, 18]. Therefore, filtering those alerts with high or average danger ratings does not 
reliably solve the issue of over-alerting. ORCA and ZHIAS consequently attempt a different 
approach, i.e. to focus on clinical management, and to record additional information in a 
categorical format. Although MediQ also contains additional information of high quality for 
clinical management in its free text comments, that information is easily overseen unless one 
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has the time to read those all. In contrast, based on its underlying categorical format ZHIAS 
can readily display that information in accordingly designed CDSS and therefore provides the 
basis to present it at first glance to the treating physician. For example, for the interaction 
between lisinopril and spironolactone (see Table 5) a CDSS using ZHIAS data could 
immediately direct the prescriber’s attention to the current serum potassium value through 
one simple activated icon or even directly trigger retrieval of the latest measurement from the 
hospital’s electronic patient information system. If potassium is indeed elevated a warning 
can be displayed with a high level of importance, whereas no further action besides 
monitoring (which could also be triggered through a ZHIAS-based system) would be required 
in case of a normal value. Furthermore, expert analysis of local results could help to put 
more emphasis on interactions that have frequently led to problems in the past in a specific 
setting or are otherwise of special interest. For example, recent data supports the view that 
not only “typical” NSAIDs but also metamizol can increase the risk of bleeding through 
inhibition of prostaglandin synthesis, which may be of special interest in a setting where this 
drug is frequently used as an analgesic after surgery [19, 20]. Finally, our finding that doses 
were apparently not adjusted for impaired renal function in 9% of all patients and in 68% of 
patients with a GFR <60 ml/min emphasizes that automated warnings for dose adjustment 
should also be part of integrated CPOE and CDSS. 
Overall our results suggest that both, the integration of CDSS into the daily clinical 
prescription workflow as well as their design and content require major changes in order to 
effectively improve medication safety in real-life settings. First, interaction alerts must be 
automatically displayed at the time of prescription. Second, in order to avoid over-alerting by 
automated CDSS a paradigm shift may be necessary, away from CDSS with maximum 
sensitivity but instead towards CDSS with the best possible specificity for clinically relevant 
alerts. Third, we must therefore increase our efforts to define clinically relevant interactions 
and consider risk factors in order to implement that information into improved CDSS. The 
implementation of ZHIAS into CDSS is one possible solution that we explored in the current 
study. Additional studies will now be necessary in order to show whether accordingly 
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modified CDSS are able to actually modify prescribing behavior and reduce adverse drug 
events. However, we also conclude that any CDSS can only change prescribing behavior if 
its introduction is well coordinated and flanked by intense personal communication with local 
prescribers, further local customization and subsequent constant reevaluations. This process 
calls for a bridging function between theoretical pharmacological knowledge and clinical 
expertise, which can be a challenging new task for clinical pharmacologists. In our case, we 
discussed critical interactions and doses with the prescribing surgeons, and next we aim to 
introduce automated alerts at the time of prescriptions that are locally co-developed and 
supported by the department of surgery, followed by a systematic outcome evaluation. 
 
 
CONCLUSIONS 
This study used a new method for automated analysis of pharmacotherapy with CDSS and 
was therefore able to identify drug interactions in prescription data of a selected patient 
population with high efficiency. Results of such retrospective analyses can be used for the 
development of targeted measures to improve medication safety, directly where they have 
been identified in the past. Reclassification of the identified interactions according to a 
multidimensional operational interaction classification system suggests that only a minor 
fraction of all identified interactions involves a substantial risk. The implementation of such a 
classification into refined CDSS may reduce over-alerting and improve usability and therefore 
efficacy of CDSS to prevent adverse drug events in clinical practice. Future studies should 
investigate the impact of this approach on the prevention of adverse drug events in clinical 
practice. 
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7. TABLES 
 
Table 1  Characteristics of the study patients (N=509) 
Characteristics  
 n % 
Sex   
   Female 280 55.0 
   Male 229 45.0 
   
Age category (years)   
   <25 20 3.9 
   25-44 46 9.0 
   45-64 138 27.1 
   65-84 243 47.7 
   85 and older 62 12.2 
   
Primary admission diagnosis1   
   Trauma 209 41.1 
   Visceral surgery 121 23.8 
   Orthopedics 101 19.8 
   Urology 22 4.3 
   Other 56 11.0 
   
Admission   
   Elective 196 38.5 
   Emergency 313 61.5 
   
Duration of hospitalization (nights)   
   4-6 173 34.0 
   7-10 152 29.9 
   11-30 172 33.8 
   >30 12 2.4 
   
Renal function (MDRD-GFR, ml/min/1.73 m2)2   
   ≥60 408 80.2 
   30-59 61 12.0 
   <30 or dialysis 4 0.8 
   Unknown 36 7.1 
   
Number of concomitant drugs (polypharmacy)   
   2-4 250 49.1 
   5-8 173 34.0 
   ≥9 86 16.9 
    
 
1Only one primary diagnosis per patient; 2Last measurement before discharge 
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Table 2  Discharge medication of the study population 
 
Drugs n prescriptions n patients with prescriptions 
 n % n % 
Total 2,729 100 509 100 
NSAIDs including paracetamol and metamizol1 712 26.1 446 87.6 
Antithrombotics1 447 16.4 316 62.1 
RAA system inhibitors and diuretics 280 10.3 178 35.0 
Other cardiovascular agents 249 9.1 168 33.0 
Gastrointestinal agents 228 8.4 204 40.1 
Anti-infective agents 143 5.2 109 21.4 
Dietary supplements 123 4.5 76 14.9 
Opioids 82 3.0 74 14.5 
Antidepressants 79 2.9 63 12.4 
Antidiabetic agents 78 2.9 51 10.0 
Other nervous system agents 53 1.9 44 8.6 
Anxiolytics, sedatives and hypnotics 49 1.8 43 8.4 
Antipsychotics 47 1.7 40 7.9 
Hormones 45 1.6 41 8.1 
Respiratory tract agents 37 1.4 24 4.7 
Anticonvulsants 28 1.0 24 4.7 
Antineoplastic and immunological agents 7 0.3 7 1.4 
Other 42 1.5 39 7.7 
 
1 Including low dose acetylsalicylic acid, which is not included among NSAIDs 
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Table 3  Identification and grading of interactions by MediQ and subsequent reclassification 
based on ORCA criteria for MediQ level 2 and 3 alerts as part of the ZHIAS classification 
 
Drug interaction classifications 
Frequency of 
distinct 
combinations in 509 
studied patients 
Frequency of 
combined 
prescriptions in 509 
studied patients 
 n % n % 
     
MediQ level 3 (“high”) 5 100 10 100 
    ORCA level 1 (“contraindicated”) 0 0 0 0 
    ORCA level 2 (“provisionally contraindicated”) 1 20.0 1 10.0 
    ORCA level 3 (“conditional risk”) 3 60.0 8 80.0 
    ORCA level 4 (“minimal risk”) 1 20.0 1 10.0 
     
MediQ level 2 (“average”) 149 100 551 100 
    ORCA level 1 (“contraindicated”) 9 6.0 10 1.8 
    ORCA level 2 (“provisionally contraindicated”) 10 6.7 76 13.8 
    ORCA level 3 (“conditional risk”) 94 63.1 302 54.8 
    ORCA level 4 (“minimal risk”) 36 24.2 163 29.6 
     
MediQ level 1 (“low”) 529 100 1,997 100 
     
MediQ level 0 (“no interaction”) 499 100 1,849 100 
     
 
  20 
Table 4  ZHIAS reclassification by ORCA categories of all 5611 interactions classified by 
MediQ as high or average danger and their corresponding frequencies in the study 
population. 
 
ZHIAS classification Frequencies in 509 patients, stratified over ORCA classes 
  
 
ORCA 1 
(contraindicated / risk 
outweighs benefit) 
ORCA 2 
(provisionally 
contraindicated) 
ORCA 3 
(conditional risk) 
 n % n % n % 
TOTAL combinations 10 100 77 100 310 100 
       
Management       
Desired 0 0 22 28.6 68 21.9 
Consider alternative 10 100 55 71.4 247 79.7 
Monitoring 0 0 77 100 263 84.8 
       
Mechanism2       
Pharmacokinetic 0 0 6 7.8 56 18.1 
Pharmacodynamic 10 100 74 96.1 275 88.7 
       
Adverse events with increased risk resulting from interactions3 
Increased drug effect 8 80.0 75 97.4 216 69.7 
Decreased drug effect 1 10.0 1 1.3 46 14.8 
Sedation (CNS) 4 40.0 5 6.5 17 5.5 
Serotonin syndrome 1 10.0 1 1.3 21 6.8 
Extrapyramidal symptoms 0 0 1 1.3 1 0.3 
Seizures 2 20.0 1 1.3 17 5.5 
CNS effects other 3 30.0 2 2.6 6 1.9 
Nephrotoxicity 3 30.0 1 1.3 37 11.9 
Hepatotoxicity 0 0 0 0 4 1.3 
QTc prolongation 0 0 2 2.6 17 5.5 
Cardiac arrhythmias 0 0 3 3.9 27 8.7 
Thrombosis 0 0 0 0 6 1.9 
Bleeding 4 40.0 70 90.9 171 55.2 
Blood pressure up 0 0 0 0 34 11.0 
Blood pressure down 1 10.0 3 3.9 22 7.1 
Cardiovascular effects other 0 0 0 0 11 3.5 
Hyperkalemia 1 10.0 0 0 39 12.6 
Hypokalemia  0 0 0 0 9 2.9 
Hyponatremia 0 0 1 1.3 5 1.6 
Metabolic/endocrine effects  0 0 1 1.3 1 0.3 
Gastrointestinal toxicity 2 20.0 1 1.3 8 2.6 
Blood glucose up 0 0 1 1.3 2 0.6 
Blood glucose down 0 0 0 0 2 0.6 
Muscular toxicity 0 0 1 1.3 7 2.3 
Allergy 0 0 0 0 4 1.3 
Other 0 0 0 0 8 2.6 
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1 Another 164 interactions classified by MediQ as high or average danger were reclassified into ORCA 
4 = minimal risk (see Table 3) and are not shown in detail in this table. 
 
2 PK and PD mechanisms can be involved concomitantly and combined total may therefore exceed 
100% 
 
3 Several adverse events may result from one combination and combined total may therefore exceed 
100% 
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Table 5  Presentation of all specific interactions with the highest severity rating according to 
MediQ (“high danger”) and/or ZHIAS (ORCA 1, “contraindicated / risk always outweighs 
benefit”)  
 
 
1 ORCA notation: 1 – contraindicated, 2 – provisionally contraindicated, 3 – conditional risk. 
2 D = desired interaction; A = consider an available alternative; M = special monitoring recommended 
 
Drug combination 
Frequency 
in 509 
patients 
MediQ 
danger 
rating 
ZHIAS classification 
ORCA1 Management2 Adverse event with increased risk 
 n %     
       
Lisinopril - spironolactone 5 1.0 High 3 A / M Hyperkalemia 
Atorvastatin - amiodarone 2 0.4 High 3 A / M Muscle toxicity 
Paroxetine  - metoprolol 1 0.2 High 2 A / M Hypotension, bradycardia 
Salmeterol - amiodarone 1 0.2 High 3 M QTc, arrhythmias 
Melitracen - amiodarone 1 0.2 High 4 M QTc, arrhythmias 
       
Tramadol - oxycodone 2 0.4 Average 1 A Sedation, seizures 
Tramadol - buprenorphine 1 0.2 Average 1 A Sedation, seizures 
Tramadol - codeine 1 0.2 Average 1 A Sedation, seizures 
Tramadol - fentanyl 1 0.2 Average 1 A Sedation, seizures, serotonin syndrome 
Lisinopril - irbesartan 1 0.2 Average 1 A Hyperkalemia, renal deterioration 
Ginkgo biloba - 
phenprocoumon 1 0.2 Average 1 A Bleeding 
Ginkgo biloba - clopidogrel 1 0.2 Average 1 A Bleeding 
Mefenamic acid - 
diclofenac 1 0.2 Average 1 A GI bleeding 
Mefenamic acid - 
ibuprofen 1 0.2 Average 1 A GI bleeding 
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Table 6  Presentation of all specific drug interactions classified by ZHIAS as ORCA 2 
(“provisionally contraindicated”), and the 10 most frequent classified as ORCA 3 (“conditional 
risk”) in 509 analyzed patients. 
Combination name Frequency in 509 patients 
MediQ 
danger 
rating 
ORCA1 Management2 Adverse event with increased risk 
 n %     
All combinations classified as “provisionally contraindicated” by ZHIAS 
Mefenamic acid - 
phenprocoumon 48 9.4 Average 2 A / M Bleeding 
Low dose acetylsalicylic 
acid - phenprocoumon 20 3.9 Average 2 D / M Bleeding 
Any two benzodiazepines 2 0.4 Average 2 D / M Sedation 
Metoprolol - paroxetine 1 0.2 High 2 A / M Bradycardia, hypotension 
Amiodarone - nebivolol 1 0.2 Average 2 A / M Bradycardia, hypotension 
Fluoxetine - citalopram 1 0.2 Average 2 A / M Hyponatremia, serotonin syndrome 
Ginkgo biloba - 
mefenamic acid 1 0.2 Average 2 A / M Bleeding 
Lithium - mefenamic acid 1 0.2 Average 2 A / M Lithium intoxication 
Quetiapine - primidone 1 0.2 Average 2 A / M Sedation, loss of quetiapine efficacy 
Valproic acid - 
phenobarbital 1 0.2 Average 2 A / M Sedation, other CNS 
10 most frequent combinations classified as “conditional risk” by ZHIAS 
Mefenamic acid - 
dalteparin 69 13.6 Average 3 A / M Bleeding 
Low dose acetylsalicylic 
acid - dalteparin 31 6.1 Average 3 D / M Bleeding 
Metamizol - 
phenprocoumon 28 5.5 Average 3 A / M Bleeding 
Mefenamic acid - 
metamizol 12 2.4 Average 3 D / M Bleeding 
Mefenamic acid - 
lisinopril 10 2.0 Average 3 A / M 
Hypertension, 
nephrotoxicity 
Diclofenac - dalteparin 8 1.6 Average 3 A / M Bleeding 
Tramadol - citalopram/ 
escitalopram 6 1.2 Average 3 A / M Serotonin syndrome 
Allopurinol - amoxicillin 4 0.8 Average 3 A / M Exanthema, skin rashes 
Allopurinol - 
phenprocoumon 4 0.8 Average 3 M Bleeding 
Tramadol - quetiapine 4 0.8 Average 3 A / M Sedation, seizures 
1 ORCA notation: 1 – contraindicated, 2 – provisionally contraindicated, 3 – conditional risk. 
2 D = desired interaction; A = consider an available alternative; M = special monitoring recommended 
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Table 7  Prescriptions without recommended dose adjustment for impaired renal function 
 
Drug n prescriptions w/o adjustment 
GFR 
range 
(ml/min) 
Recomm. max. 
dose (mg/day) 
Actual dose 
range (mg/day) 
Risk of related 
adverse event 
      
Metformin 8 30-59 850 1,000-1,700 Major 
Diclofenac 2 39-57 75 100-150 Major1 
Metamizol 2 29-30 Avoid high doses 4,000 Major1 
Perindopril 1 48 2 8 Major1  
Rosuvastatin 1 25 Avoid 10 Major 
      
Paracetamol 39 25-59 2,500 4,000 Minor  
Atenolol 1 32 50 75 Minor  
Hydrochlorothiazide 1 29 Avoid 12.5 Minor  
Pregabalin 1 51 300 375 Minor  
      
 
1 The combination of NSAIDs, ACE-inhibitors and preexisting renal impairment is an important risk 
factor for acute renal failure, particularly if doses are not adjusted.
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8. FIGURES 
 
 
Fig. 1 Overview of study procedures and global results 
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Fig. 2   Correlation between polypharmacy and identification of interactions by different              
danger categories for interactions according to MediQ 
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